Drugs Made In America Acquisition II Corp.(DMII)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DMII Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Drugs Made In America Acquisition II Corp. (DMII), a Financials sector company. DMII is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Drugs Made In America Acquisition II Corp. reports net income of $4.3M, free cash flow of $-102.5K. Top institutional holders of DMII by reported 13-F value include Magnetar Financial, MMCAP International SPC, Karpus Management,, based on the most recent SEC filings. DMII trades on the Nasdaq exchange and files with the SEC under CIK 2040475. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DMII daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Drugs Made In America Acquisition II Corp. directly from SEC EDGAR.
Net Income
Q1 2026
$4.3M
Free Cash Flow
Q1 2026
$-102.5K
AI Insight: DMII Financial Trends
DMII shows persistent negative equity across three quarters with minimal operating activity.
• Equity deteriorated from -$17M (Q3 2025) to -$18M (Q1 2026), indicating cumulative losses exceed book value.
• Net income of $4M in Q4 2025 and Q1 2026 insufficient to offset equity deficit or generate meaningful cash flow.
⚠ Operating cash flow and operating income remain near zero; capital structure unstable with negative shareholder equity.
⚠ Revenue data absent across all periods; unable to assess core business traction or operational scale.
AI Insight: DMII Ratio Trends
Insufficient data to identify meaningful trends; only ROA available across three quarters with no operational metrics.
• ROA flat at 3.4% in Q4 2025 and Q1 2026, suggesting stable but minimal profitability on assets.
⚠ Near-complete absence of margin, leverage, and ROIC data prevents assessment of operational efficiency or capital deployment.
Get alerted when DMII's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Drugs Made In America Acquisition II Corp. including:
Top Institutional Holders of DMII
Magnetar Financial LLC
$26.9M2,700,000 shMMCAP International Inc. SPC
$26.9M2,700,000 shKarpus Management, Inc.
$25.9M2,597,923 shLMR Partners LLP
$20.1M2,000,000 shHEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
$20.0M2,000,000 shMILLENNIUM MANAGEMENT LLC
$19.7M1,976,425 shHudson Bay Capital Management LP
$19.7M1,969,030 shWOLVERINE ASSET MANAGEMENT LLC
$17.9M1,795,291 shPolar Asset Management Partners Inc.
$15.0M1,500,000 shTENOR CAPITAL MANAGEMENT Co., L.P.
$15.0M1,500,000 sh
| Fund | Value | Shares |
|---|---|---|
| Magnetar Financial LLC | $26.9M | 2,700,000 |
| MMCAP International Inc. SPC | $26.9M | 2,700,000 |
| Karpus Management, Inc. | $25.9M | 2,597,923 |
| LMR Partners LLP | $20.1M | 2,000,000 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $20.0M | 2,000,000 |
| MILLENNIUM MANAGEMENT LLC | $19.7M | 1,976,425 |
| Hudson Bay Capital Management LP | $19.7M | 1,969,030 |
| WOLVERINE ASSET MANAGEMENT LLC | $17.9M | 1,795,291 |
| Polar Asset Management Partners Inc. | $15.0M | 1,500,000 |
| TENOR CAPITAL MANAGEMENT Co., L.P. | $15.0M | 1,500,000 |
More Financials Companies
View all Financials →Put DMII on your watchlist
Track score changes the day Drugs Made In America Acquisition II Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DMII a good stock to buy?
13F Pro's AI-powered analysis of Drugs Made In America Acquisition II Corp. (DMII) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Financials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DMII are available on the DMII stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own DMII?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DMII. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Drugs Made In America Acquisition II Corp.'s investment landscape.